Advertisement

European Archives of Oto-Rhino-Laryngology

, Volume 276, Issue 3, pp 879–887 | Cite as

Bacteriotherapy with Streptococcus salivarius 24SMB and Streptococcus oralis 89a oral spray for children with recurrent streptococcal pharyngotonsillitis: a randomized placebo-controlled clinical study

  • Claudio AndaloroEmail author
  • Maria Santagati
  • Stefania Stefani
  • Ignazio La Mantia
Miscellaneous
  • 137 Downloads

Abstract

Purpose

Group A beta-hemolytic Streptococcus (GABHS) causes a recurrent acute pharyngotonsillitis (RAPT) in children. Moreover, the repeated use of antibiotics contributes to its resistance. However, S. Salivarius 24SMB and S. oralis 89a were effective probiotics in other infections. Thus, we decided to evaluate this combination efficacy compared to placebo in RAPT.

Methods

Patients with microbiologically confirmed GABHS were enrolled in this randomized, placebo-controlled trial. They received the aforementioned combination or placebo as an oral spray. We investigated episodes of frequency and duration, need for antibiotics, school days lost, the treatment impact on life quality, treatment compliance and side effects during a 90-day treatment and a 6-month follow-up.

Results

We included 41 patients in each group. The mean number of GABHS infection was significantly lower during both study periods for the two groups. However, our treatment group showed a lower rate. Moreover, the probiotic group had a lower mean number and a shorter median duration of GABHS episodes during both study periods than controls. Furthermore, the mean duration of antibiotic treatment was lower in the probiotic group during the 90-day and 6-month follow-up periods. Similarly, patients in the probiotic group showed a significantly lower mean number of absence days from school but higher EQ-VAS score. Indeed, all patients included were compliant to treatment.

Conclusions

We identified potential probiotics, possessing desirable features against GABHS pharyngotonsillitis. Our findings represent the first evidence which throws the light on using these probiotics that can reduce antibiotics use which did not have efficient results regarding recurrence.

Keywords

Streptococcus pyogenes Tonsillitis Streptococcus salivarius Probiotics 

Notes

Funding

None.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the institutional committee of the School of Medicine—ASP 3 Catania (ID: 083/17) and with the 1964 Helsinki declaration.

Informed consent

Informed consent was obtained from all parents of children included in the study.

References

  1. 1.
    Gregori G, Righi O, Risso P, Boiardi G, Demuru G, Ferzetti A et al (2016) Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study. Ther Clin Risk Manag 12:87–92CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Koskenkorva T, Koivunen P, Koskela M, Niemela O, Kristo A, Alho OP (2013) Short-term outcomes of tonsillectomy in adult patients with recurrent pharyngitis: a randomized controlled trial. CMAJ 185:331–336CrossRefGoogle Scholar
  3. 3.
    Torretta S, Rosazza C, Pace ME, Iofrida E, Marchisio P (2017) Impact of adenotonsillectomy on pediatric quality of life: review of the literature. Ital J Pediatr 43:107CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Munck H, Jørgensen AW, Klug TE (2018) Antibiotics for recurrent acute pharyngo-tonsillitis: systematic review. Eur J Clin Microbiol Infect Dis 2018:1–10Google Scholar
  5. 5.
    La Mantia I, Varricchio A, Ciprandi G (2017) Bacteriotherapy with Streptococcus salivarius 24SMB and Streptococcus oralis 89a nasal spray for preventing recurrent acute otitis media in children: a real-life clinical experience. Int J Gen Med 10:171–175CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Di Pierro F, Adami T, Rapacioli G, Giardini N, Streitberger C (2013) Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults. Expert Opin Biol Ther 13:339–343CrossRefPubMedGoogle Scholar
  7. 7.
    Burton MJ, Glasziou PP, Chong LY, Venekamp RP (2014) Tonsillectomy or adenotonsillectomy versus non-surgical treatment for chronic/recurrent acute tonsillitis. Cochrane Database Syst Rev 11:CD001802Google Scholar
  8. 8.
    Falagas ME, Rafailidis PI, Makris GC (2008) Bacterial interference for the prevention and treatment of infections. Int J Antimicrob Agents 31:518–522CrossRefPubMedGoogle Scholar
  9. 9.
    Esposito S, Rigante D, Principi N (2014) Do children’s upper respiratory tract infections benefit from probiotics? BMC Infect Dis 14:194CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Koboziev I, Reinoso Webb C, Furr KL, Grisham MB (2014) Role of the enteric microbiota in intestinal homeostasis and inflammation. Free Radic Biol Med 68:122–133CrossRefPubMedGoogle Scholar
  11. 11.
    Ashraf R, Shah NP (2014) Immune system stimulation by probiotic microorganisms. Crit Rev Food Sci Nutr 54:938–956CrossRefPubMedGoogle Scholar
  12. 12.
    Lenoir-Wijnkoop I, Sanders ME, Cabana MD, Caglar E, Corthier G, Rayes N, Sherman PM, Timmerman HM, Vaneechoutte M, Van Loo J et al (2007) Probiotic and prebiotic influence beyond the intestinal tract. Nutr Rev 65:469–489CrossRefPubMedGoogle Scholar
  13. 13.
    Marchisio P, Santagati M, Scillato M, Baggi E, Fattizzo M, Rosazza C, Stefani S, Esposito S, Principi N (2015) Streptococcus salivarius 24SMB administered by nasal spray for the prevention of acute otitis media in otitis-prone children. Eur J Clin Microbiol Infect Dis 34:2377–2383CrossRefPubMedGoogle Scholar
  14. 14.
    Santagati M, Scillato M, Muscaridola N, Metoldo V, La Mantia I, Stefani S (2015) Colonization, safety, and tolerability study of the Streptococcus salivarius 24SMBc nasal spray for its application in upper respiratory tract infections. Eur J Microbiol Infect Dis 34:2075–2080CrossRefGoogle Scholar
  15. 15.
    Santagati M, Scillato M, Patanè F, Aiello C, Stefani S (2012) Bacteriocin-producing oral streptococci and inhibition of respiratory pathogens. FEMS Immunol Med Microbiol 65:23–31CrossRefPubMedGoogle Scholar
  16. 16.
    Gilbey P, Livshits L, Sharabi-Nov A, Avraham Y, Miron D (2015) Probiotics in addition to antibiotics for the treatment of acute tonsillitis: a randomized, placebo-controlled study. Eur J Clin Microbiol Infect Dis 34:1011–1015CrossRefPubMedGoogle Scholar
  17. 17.
    Wescombe PA, Hale JD, Heng NC, Tagg JR (2012) Developing oral probiotics from Streptococcus salivarius. Future Microbiol 7:1355–1371CrossRefPubMedGoogle Scholar
  18. 18.
    Sidjabat HE, Håkansson EG, Cervin A (2016) Draft genome sequence of the oral commensal Streptococcus oralis 89a with interference activity against respiratory pathogens. Genome Announc 4:e01546–e01515CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kalra MG, Higgins KE, Perez ED (2016) Common questions about streptococcal pharyngitis. Am Fam Phys 94:24–31Google Scholar
  20. 20.
    Shulman ST, Bisno AL, Clegg HW, Gerber MA, Kaplan EL, Lee G, Martin JM, Van Beneden C (2012) Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis 55:e86–e102CrossRefPubMedGoogle Scholar
  21. 21.
    Brook I (1999) Bacterial interference in upper respiratory tract infections. Crit Rev Microbiol 25:155–172CrossRefPubMedGoogle Scholar
  22. 22.
    Power DA, Burton JP, Chilcott CN, Dawes PJ, Tagg JR (2008) Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. Eur J Clin Microbiol Infect Dis 27:1261–1263CrossRefPubMedGoogle Scholar
  23. 23.
    Roos K, Håkansson EG, Holm S (2001) Effect of recolonisation with “interfering” a streptococci on recurrences of acute and secretory otitis media in children: randomised placebo controlled trial. Br Med J 322:1–4CrossRefGoogle Scholar
  24. 24.
    Skovbjerg S, Roos K, Holm SE, Grahn Hakansson E, Nowrouzian F, Ivarsson M, Adlerberth I, Wold AE (2009) Spray bacteriotherapy decreases middle ear fluid in children with secretory otitis media. Arch Dis Child 94:92–98CrossRefPubMedGoogle Scholar
  25. 25.
    Regev-Yochay G, Trzcinski K, Thompson CM, Malley R, Lipsitch M (2006) Interference between Streptococcus pneumoniae and Staphylococcus aureus: in vitro hydrogen peroxide-mediated killing by Streptococcus pneumoniae. J Bacteriol 188:4996–5001CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Horz HP, Meinelt A, Houben B, Conrads G (2007) Distribution and persistence of probiotic Streptococcus salivarius K12 in the human oral cavity as determined by real-time quantitative polymerase chain reaction. Oral Microbiol Immunol 22:126–130CrossRefPubMedGoogle Scholar
  27. 27.
    Di Mario S, Basevi V, D’Amico R, Gagliotti C, Gangemi M, Marchetti F, Moro ML, Tamburlini G (2016) Streptococcus salivarius by nasal spray for recurrent otitis: how good is the evidence? Eur J Clin Microbiol Infect Dis 35:1215–1216CrossRefPubMedGoogle Scholar
  28. 28.
    Wescombe PA, Heng NCK, Burton JP, Chilcott CN, Tagg JR (2009) Streptococcal bacteriocins and the case for Streptococcus salivarius as model oral probiotics. Future Microbiol 4:819–835CrossRefPubMedGoogle Scholar
  29. 29.
    Tagg JR (2004) Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius. Indian J Med Res 119:13–16PubMedGoogle Scholar
  30. 30.
    Burton JP, Chilcott CN, Moore CJ, Speiser G, Tagg JR (2006) A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J Appl Microbiol 100:754–764CrossRefPubMedGoogle Scholar
  31. 31.
    Tano K, Grahn Hakansson E, Holm SE, Hellstrom S (2002) A nasal spray with alpha-haemolytic streptococci as long term prophylaxis against recurrent otitis media. Int J Pediatr Otorhinolaryngol 62:17–23CrossRefPubMedGoogle Scholar
  32. 32.
    Roos K, Holm SE, Grahn-Hakansson E, Lagergren L (1996) Recolonization with selected alpha-streptococci for prophylaxis of recurrent streptococcal pharyngotonsillitis—a randomized placebo-controlled multicentre study. Scand J Infect Dis 28:459–462CrossRefPubMedGoogle Scholar
  33. 33.
    Bernstein JM, Haase E, Scannapieco F, Dryja D, Wolf J, Briles D, King J, Wilding GE (2006) Bacterial interference of penicillin-sensitive and -resistant Streptococcus pneumoniae by Streptococcus oralis in an adenoid organ culture: implications for the treatment of recurrent upper respiratory tract infections in children and adults. Ann Otol Rhinol Laryngol 115:350–356CrossRefPubMedGoogle Scholar
  34. 34.
    Burton JP, Chilcott CN, Tagg JR (2005) The rationale and potential for the reduction of oral malodour using Streptococcus salivarius probiotics. Oral Dis 11:29–31CrossRefPubMedGoogle Scholar
  35. 35.
    Miller SI, Ernst RK, Bader MW (2005) LPS, TLR4 and infectious disease diversity. Nat Rev Microbiol 3:36–46CrossRefPubMedGoogle Scholar
  36. 36.
    Schiffrin EJ, Rochat F, Link-Angler H, Acschlimann JM, Donnet-Hughes A (1995) Immuno-modulation of human blood cells following the ingestion of lactic acid bacteria. J Dairy Sci 78:491–497CrossRefPubMedGoogle Scholar
  37. 37.
    Majamaa H, Isolauri E, Saxelin M, Vesikari T (1995) Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr 20:333–338CrossRefPubMedGoogle Scholar
  38. 38.
    Meydani SN, Ha WK (2000) Immunologic effects of yogurt. Am J Clin Nutr 71:861–872CrossRefPubMedGoogle Scholar
  39. 39.
    Oelschlaeger TA (2010) Mechanisms of probiotic actions—a review. Int J Med Microbiol 300:57–62CrossRefPubMedGoogle Scholar
  40. 40.
    Hyink O, Wescombe PA, Upton M, Ragland N, Burton JP, Tagg JR (2007) Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl Environ Microbiol 73:1107–1113CrossRefPubMedGoogle Scholar
  41. 41.
    Sanders CC, Sanders WE Jr (1982) Enocin: an antibiotic produced by Streptococcus salivarius that may contribute to protection against infections due to group A streptococci. J Infect Dis 146:683–690CrossRefPubMedGoogle Scholar
  42. 42.
    Cox AJ, Pyne DB, Saunders PU, Fricker PA (2010) Oral administration of the probiotic Lactobacillus fermentum VRI-003 and mucosal immunity in endurance athletes. Br J Sports Med 44:222–226CrossRefPubMedGoogle Scholar
  43. 43.
    Tieu DD, Kern RC, Schleimer RP (2009) Alterations in epithelial barrier function and host defense responses in chronic rhinosinusitis. J Allergy Clin Immunol 124:37–42CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Larsen JM, Musavian HS, Butt TM, Ingvorsen C, Thysen AH, Brix S (2015) Chronic obstructive pulmonary disease and asthma-associated Proteobacteria, but not commensal Prevotella spp. promote Toll-like receptor 2-independent lung inflammation and pathology. Immunology 144:333–342CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Roos K, Holm S (2002) The use of probiotics in head and neck infections. Curr Infect Dis Rep 4:211–216CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Ear, Nose and Throat UnitSanta Marta e Santa Venera HospitalAcirealeItaly
  2. 2.LabMMAR, Department of Biomedical and Biotechnological Sciences, Section of MicrobiologyUniversity of CataniaCataniaItaly
  3. 3.Department of Medical Sciences, Surgical and Advanced Technologies, GF IngrassiaUniversity of CataniaCataniaItaly

Personalised recommendations